CytomX Therapeutics, Inc. (CTMX) Earnings History
Annual and quarterly earnings data from 2013 to 2025
Loading earnings history...
CTMX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CTMX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 100.0% | -25.7% | -22.8% |
| 2024 | 100.0% | 18.1% | 23.1% |
| 2023 | 100.0% | -6.4% | -0.6% |
| 2022 | 100.0% | -190.6% | -186.8% |
| 2021 | 100.0% | -311.0% | -310.5% |
Download Data
Export CTMX earnings history in CSV or JSON format
Free sign-in required to download data
CytomX Therapeutics, Inc. (CTMX) Earnings Overview
As of May 8, 2026, CytomX Therapeutics, Inc. (CTMX) reported trailing twelve-month net income of -$59M, reflecting -139.5% year-over-year growth. The company earned $-0.33 per diluted share over the past four quarters, with a net profit margin of -22.8%.
Looking at the long-term picture, CTMX's historical earnings data spans multiple years. The company achieved its highest annual net income of $32M in fiscal 2024.
CytomX Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), RCUS (-$369M net income, -142.9% margin), PBYI ($24M net income, 13.6% margin), CTMX has comparable earnings metrics. Compare CTMX vs IMVT →
CTMX Earnings vs Peers
Earnings metrics vs comparable public companies
CTMX Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$17M | -154.5% | -$20M | $-0.15 | -22.8% | -25.7% |
| 2024 | $32M | +5700.9% | $25M | $0.38 | 23.1% | 18.1% |
| 2023 | $-569,000 | +99.4% | -$6M | $-0.01 | -0.6% | -6.4% |
| 2022 | -$99M | +14.3% | -$101M | $-1.48 | -186.8% | -190.6% |
| 2021 | -$116M | -78.8% | -$116M | $-1.26 | -310.5% | -311.0% |
| 2020 | -$65M | +36.6% | -$81M | $-0.71 | -94.7% | -117.7% |
| 2019 | -$102M | -20.8% | -$111M | $-2.26 | -177.8% | -192.9% |
| 2018 | -$85M | -96.3% | -$78M | $-2.03 | -142.2% | -130.9% |
| 2017 | -$43M | +26.8% | -$46M | $-1.16 | -60.2% | -64.6% |
| 2016 | -$59M | -66.5% | -$60M | $-1.63 | -391.5% | -396.1% |
See CTMX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTMX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTMX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCTMX — Frequently Asked Questions
Quick answers to the most common questions about buying CTMX stock.
Is CTMX growing earnings?
CTMX EPS fell to $-0.33, with earnings declining -139.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-59M.
What are CTMX's profit margins?
CytomX Therapeutics, Inc. net margin is -22.8%, with operating margin at -25.7%. Below-average margins reflect competitive or cost pressures.
How consistent are CTMX's earnings?
CTMX earnings data spans 2013-2025. The declining earnings trend is -139.5% YoY. Historical data enables comparison across business cycles.